Now a blood test can check for breast cancer!
Bertis expands the use of breast cancer early diagnosis device MASTOCHECK

to more than 60 medical institutions nationwide

- MASTOCHECK detects early breast cancer with 92% accuracy using only 1ml of blood.

- More than 60 medical institutions nationwide are now able to detect breast cancer with MASTOCHECK…

a significant advance over existing testing methods and meets the diverse needs of examinees

As many domestic hospitals and screening institutions have introduced new diagnostic services that can detect breast cancer with a single drop of blood, the convenience of breast cancer screening is increasing. 

Bertis Inc. (co-CEOs Dong-young Noh and Seung-man Han), a proteomic-based early-diagnosis biotechnology company, announced on x that Bertis signed contract with 60 medical institutions to distribute MASTOCHECK, the world first blood-based breast cancer diagnostic assay. 

MASTOCHECK, the breast cancer screening method based on proteomics, is an innovative and convenient method that can detect early breast cancer with 92% accuracy (based on the patent) using the only 1ml of blood. After measuring three breast cancer-specific biomarkers within the blood, the quantitative value is substituted into a unique patented algorithm to diagnose breast cancer. The advantage of MASTOCHECK is that it is consistent with its screening accuracy even in dense breasts cases where the accuracy of mammography, the current gold standard, decreases. Also, it is a convenient blood test that does not have the risk of any radiation exposure.

Currently, MASTOCHECK screening is available at ▲Hanaro Medical Foundation, ▲(Corp.) Hanshin Medipia Clinic affiliated by Junghae Welfare Association, ▲Yuseong/Daejeon Sun Medical Center, ▲Seoul Mirae Medical Center/Busan Mirae IFC Medical Center, ▲Health Promotion Center of CHA University (Bundang, Ilsan, Gumi) Medical Center, ▲Health Promotion Center of Dankook University Hospital, etc. There are about 60 hospitals and health check-up centers nationwide using MASTOCHECK. Also, It will be implemented in August at large centers such as the KMI (Korea Medical Research Institute). Bertis plans to continually expand  MASTOCHECK service for more examinees to choose a new breast cancer screening option. 

Specifically, as MASTOCHECK examination expands in earnest, the method is expected to compensate for the limitation of existing testing methods and meet the diverse needs of examinees △when conventional breast X-ray (mammography) examination is inconvenient, △when patients want to take a breast cancer test easily without pain, △when younger patients in their 20s to 30s want a breast cancer test, △and when patients in their childbearing period need a safe test.   

Bertis’ CEO, Seung-man Han, said, "pleased to offer an innovative breast cancer diagnosis option to customers by accomplishing contracts with multiple medical institutions. Ushering in the era of simple and accurate detection of breast cancer with MASTOCHECK, which requires only a drop of blood and eliminates worries about radiation, will continue contributing to national breast cancer prevention and early detection."

For more information on MASTOCHECK, please visit the official website (www.mastocheck.com). 

Breast cancer has the highest rate of incidence in the world. In 2018, there were 23,000 new breast cancer cases per year, and the number has doubled in the past ten years in Korea. In the case of 0, 1st, 2nd stage patients classified as early-stage breast cancer, their 5-year survival rate is higher than 90%, but that of 4th stage patients with systemic metastasis is only 34%. In addition, breast cancer can affect a woman’s self-esteem and quality of life, so it is essential to detect and treat it quickly through early diagnosis.